WebKER-047, is designed to selectively and potently inhibit activin receptor-like kinase-2, a TGF-β superfamily receptor. KER-047 is being developed for the treatment of functional iron … Web13 jun. 2024 · Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the Transforming Growth Factor-Beta receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain.
Keros Therapeutics Reports Recent Business Highlights and Third …
Web3 okt. 2024 · Promising hypertension pipeline therapies in various stages of development include Firibastat, Baxdrostat (CIN-107), MLS-101, Zilebesiran (ALN-AGT), Ifetroban, IONIS-AGT-LRx, QLS-101, ID140009,... WebPipeline Innovative Drugs Designed to Improve Patients’ Lives Our clinical-stage pipeline includes four internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies and solid tumors. perfcollect docs
Keros Therapeutics, Inc. Announces Dosing of First Participants in ...
WebKeros Therapeutics Powered by TGF-β science, inspired by patients At Keros, our mission is to innovate therapies that have the potential to shift the treatment paradigm for people … At Keros, our mission is to deliver significant clinical benefit to patients suffering from … At Keros, we are leveraging ... we have honed a deep understanding of TGF-β … The Investor Relations website contains information about Keros Therapeutics's … Careers - Keros Therapeutics Contact Us - Keros Therapeutics Ran Nussbaum has served as Chairman of our board of directors since April … Christopher Rovaldi has served as our Chief Operating Officer since February … Our Pipeline - Keros Therapeutics Web13 okt. 2024 · Emerging Myelodysplastic Syndrome pipeline therapies such as IFN-γ (interferon gamma-1b) injection, Magrolimab, ASTX030, SX-682, Tamibarotene, APR-246, Luspatercept, Seclidemstat, MBG453, and... Web14 mei 2024 · LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal … perfax bois